Summary

U.S. Liquid Embolic Agent Market Summary

The U.S. liquid embolic agent market size was estimated at USD 66.97 million in 2024 and is projected to reach USD 146.85 million by 2033, growing at a CAGR of 9.26% from 2025 to 2033. This growth is driven by technological advancements, increasing prevalence of vascular disorders, rising preference for minimally invasive procedures, advancements in embolic agent materials, and expanding application areas.

The increasing incidence of neurovascular and peripheral vascular conditions such as aneurysms, arteriovenous malformations (AVMs), and hypervascular tumors has increased demand for effective embolization solutions, fueling market expansion. These conditions often require minimally invasive procedures to block abnormal blood vessels, prevent rupture, or reduce tumor blood supply. Liquid embolic agents are particularly well-suited for these treatments because they precisely target complex vascular structures, providing effective devascularization with minimal collateral damage.

As awareness of these conditions increases and diagnostic techniques improve, more patients are diagnosed early and require embolization therapy. In addition, advancements in embolic materials, such as n-butyl cyanoacrylate (n-BCA) and ethylene vinyl alcohol copolymer (EVOH), have enhanced the safety and efficacy of these procedures, making them more attractive options for clinicians. The expanding adoption of endovascular techniques further boosts the utilization of liquid embolic agents. Consequently, this surge in neurovascular and peripheral vascular condition cases, technological progress, and growing clinical acceptance fuel market expansion. For instance, in July 2025, Medtronic announced the enrollment of the first patient in the Peripheral Onyx Liquid Embolic (PELE) clinical trial. This study aims to assess the safety and efficacy of the Onyx Liquid Embolic System (LES) for the embolization of arterial hemorrhages in the peripheral vasculature.

Liquid embolic agents are widely used in the treatment of various conditions such as arteriovenous malformations (AVMs), hypervascular tumors, peripheral hemorrhages, and other vascular anomalies. The growing incidence of stroke, cancer, and traumatic injuries has increased demand for effective embolization therapies in the country. For instance, according to Barrow Neurological Institute, approximately 300,000 Americans are affected by AVMs of the brain and spinal cord (neurological AVMs), but only around 12 percent of those affected experience symptoms.

Some of the key players operating in the U.S. and having U.S. FDA-approved products include Medtronic, CERENOVUS (Johnson & Johnson), Boston Scientific Corporation, Terumo, and Sirtex (BlackSwan Vascular, Inc.). Furthermore, the adoption of advanced embolic materials, including cyanoacrylate-based, non-adhesive, and ethylene vinyl alcohol copolymer agents, has improved procedural outcomes and safety profiles, fueling market expansion.

The trend toward outpatient procedures is also contributing to market growth, with ambulatory surgical centers increasingly adopting embolization techniques due to their cost-effectiveness and patient convenience. According to a research article published in the Interventional Neuroradiology journal in April 2022, liquid embolic systems (LESs) such as n-butyl cyanoacrylate (n-BCA) and ethylene vinyl alcohol copolymer (EVOH) are utilized for the embolization of brain arteriovenous malformations (bAVMs) to facilitate presurgical devascularization in U.S. hospitals.

U.S. Liquid Embolic Agent Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. liquid embolic agent market report based on product, application, and end use:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Ethylene Vinyl Alcohol Copolymer (EVOH)
• Cyanoacrylates
o N-BCA
o N-HCA
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Arteriovenous Malformations (AVM)
• Hypervascular Tumors
• Peripheral Vasculature Hemorrhage
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Specialty Clinics
• Ambulatory Surgery Centers
• Other End Use

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Application
1.2.3. End Use
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.5.5. Information Analysis
1.5.6. Data Analysis Models
1.6. Market Formulation & Data Visualization
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. List of Secondary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. U.S. Liquid Embolic Agent Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing incidence of conditions such as arteriovenous malformations (AVMs), aneurysms, and hemorrhages necessitates embolization procedures
3.2.1.2. Advancements in embolization technologies
3.2.1.3. Increasing adoption in oncology treatments
3.2.2. Market Restraint Analysis
3.2.2.1. High cost of materials and procedures
3.2.2.2. Strict regulatory approvals and compliance
3.2.3. Market Opportunities Analysis
3.2.3.1. Emerging applications
3.2.4. Market Challenges Analysis
3.3. U.S. Liquid Embolic Agent Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political & Legal Landscape
3.3.2.2. Economic and Social Landscape
3.3.2.3. Technological landscape
Chapter 4. U.S. Liquid Embolic Agent Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. U.S. Liquid Embolic Agent Market Product Movement Analysis
4.3. U.S. Liquid Embolic Agent Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.4. Ethylene Vinyl Alcohol Copolymer (EVOH)
4.4.1. Ethylene Vinyl Alcohol Copolymer (EVOH) U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Cyanoacrylates
4.5.1. Cyanoacrylates U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.2. N-BCA
4.5.2.1. N-BCA U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.3. N-HCA
4.5.3.1. N-HCA U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Others
4.6.1. Others U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. U.S. Liquid Embolic Agent Market: Application Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. U.S. Liquid Embolic Agent Market Application Movement Analysis
5.3. U.S. Liquid Embolic Agent Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
5.4. Arteriovenous Malformations (AVM)
5.4.1. Arteriovenous Malformations (AVM) U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Hypervascular Tumors
5.5.1. Hypervascular Tumors U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Peripheral Vasculature Hemorrhage
5.6.1. Peripheral Vasculature Hemorrhage U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. Others
5.7.1. Others U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. U.S. Liquid Embolic Agent Market: End Use Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. U.S. Liquid Embolic Agent Market End Use Movement Analysis
6.3. U.S. Liquid Embolic Agent Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
6.4. Hospitals
6.4.1. Hospitals U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Specialty Clinics
6.5.1. Specialty Clinics U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Ambulatory Surgery Centers
6.6.1. Ambulatory Surgery Centers U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Other End Use
6.7.1. Other End Use U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Market Participant Categorization
7.2. Key Company Profiles
7.2.1. Medtronic
7.2.1.1. Company Overview
7.2.1.2. Financial Performance
7.2.1.3. Product Benchmarking
7.2.1.4. Strategic Initiatives
7.2.2. Terumo
7.2.2.1. Company Overview
7.2.2.2. Financial Performance
7.2.2.3. Product Benchmarking
7.2.2.4. Strategic Initiatives
7.2.3. Boston Scientific Corporation
7.2.3.1. Company Overview
7.2.3.2. Financial Performance
7.2.3.3. Product Benchmarking
7.2.3.4. Strategic Initiatives
7.2.4. Johnson & Johnson
7.2.4.1. Company Overview
7.2.4.2. Financial Performance
7.2.4.3. Product Benchmarking
7.2.4.4. Strategic Initiatives
7.2.5. Sirtex (BlackSwan Vascular, Inc.)
7.2.5.1. Company Overview
7.2.5.2. Financial Performance
7.2.5.3. Product Benchmarking
7.2.5.4. Strategic Initiatives
7.2.6. Others
7.2.6.1. Company Overview
7.2.6.2. Financial Performance
7.2.6.3. Product Benchmarking
7.2.6.4. Strategic Initiatives
7.3. Company Market Share Analysis, 2024
7.4. List of Other Key Market Players